Comparison of first antiretroviral treatment duration and outcome in HIV, HIV-HBV and HIV-HCV infection

International Journal of STD and AIDS

Volumn 18, Issue 8, 2007, Pages 546-550

  Cooper, Curtis L ^a,b,d   Mills, Ed ^b,c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b Centre for International Health and Human Rights Studies   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

HAART; HCV; HIV; Liver

Indexed keywords

ANTIRETROVIRUS AGENT; DELAVIRDINE; EFAVIRENZ; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL TOXICITY; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; LONGEVITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MIXED INFECTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK; SIDE EFFECT; SUBSTANCE ABUSE; TREATMENT DURATION; TREATMENT OUTCOME; DRUG ADMINISTRATION; RETROSPECTIVE STUDY;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 38449101201     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/095646207781439838     Document Type: Article

References (15)

1. Sherman KE, Roustrer S, Chung R, et al. Hepatitis C: prevalence in HIV-infected patients across sectional analysis of the US ACTG. Antivir Ther 2000;5(Suppl 1):64-5
2. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52
3. Benhamou Y, Di Martino V, Bochet M, et al. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001;34:283-7
4. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999;30:1054-8
5. Rosenthal E, Poiree M, Pradier C, et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 2003;17:1803-9
6. Qurishi N, Kreuzberg C, Luchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003;362:1708-13
7. Sulkowski MS, Thomas DL, Chaisson RE, et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000;283:74-80
8. Cooper CL, Parbhakar MA, Angel JB. Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2002;34:1259-63
9. Puoti M, Torti C, Ripamonti D, et al. Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. J Acquir Immune Defic Syndr 2003;32:259-67
10. Nunez M, Lana R, Mendoza JL, et al. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001;27:426-31
11. Klein MB, Willemot P, Murphy T, et al. The impact of initial highly active antiretroviral therapy on future treatment sequences in HIV infection. AIDS 2004;18:1895-904
12. Developed by the Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. 2003
13. Sullivan PS, Hanson DL, Teshale EH, et al. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy. AIDS 2006;20:1171-9
14. Lucas GM, Cheever LW, Chaisson RE, et al. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr 2001;27:251-9
15. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000;14:357-66